The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Limaprost     (E)-7-[(1R,2S,3R)-3-hydroxy- 2-[(E,3S,5S)-3...

Synonyms: Limaprostum, SureCN373011, ONO-1206, CHEMBL2107456, OP-1206, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of ONO 1206

  • Rapid effect of oral limaprost in Raynaud's disease in childhood [1].
  • A synthetic analog of prostaglandin E(1), OP-1206 (17S,20-dimethyl-trans-Delta(2)-prostaglandin E(1); 0.5 microg/kg body weight) was orally administered to rats twice a day for 5 days [2].
  • Rats were treated orally with 300 micrograms/kg/day OP-1206 alpha-cyclodextrin clathrate (OP-1206), a stable PGE1 analogue, for 14 days after photodynamic retinal vascular thrombosis by rose Bengal [3].
  • Six hours after the sixth-administration of OP-1206, the level of the thermal hyperesthesia was attenuated in a dose-dependent manner, and this effect lasted more than 1 day after the last drug administration [4].
  • These data show that oral treatment with OP-1206 alpha-CD is effective in improving walking dysfunction induced by spinal canal stenosis, and this therapeutic effect is likely mediated by improved SCBF at the territory of spinal stenosis [5].

Psychiatry related information on ONO 1206


High impact information on ONO 1206

  • In a morphometric analysis of myelinated nerve fibers (MNFs) in long-term diabetes, the mean diameter of the largest 10% of MNFs was significantly reduced in untreated diabetic compared with control rats, but OP-1206 completely reversed this reduction [7].
  • OP-1206 increased phosphorylation of the 50,000 mol. wt vasodilator-stimulated phosphoprotein, at concentrations of 7.9-79 nM, which inhibited aggregation induced by STA2 [8].
  • (8R*, 9S*, 11S*)-(-)-9-Hydroxy-9-n-hexyloxy-8-methyl-2,3,9,10- tetrahydro-8,11-epoxy-1H, 8H, 11H-2, 7b, 11a-triazadibenzo(a,g)-cycloocta(c,d,e)trinden-1-one (KT-5720), a specific inhibitor of A kinase, not only reversed the inhibition by OP-1206 of STA2-induced platelet aggregation, but also inhibited the OP-1206-induced protein phosphorylation [8].
  • We have recently reported that coadministration of 17 S,20-dimethyl- trans- lower right triangle (2)-prostaglandin E(1) (OP-1206), a stable synthetic analogue of prostaglandin E(1), with 5-FU to rats protects the small intestine from 5-FU-induced damage [9].
  • The present study provides evidence that oral treatment with the prostaglandin E1 analog (OP-1206 alpha-CD) is effective in improving motor dysfunction and spinal cord blood flow in rats with spinal compression [5].

Chemical compound and disease context of ONO 1206


Biological context of ONO 1206


Anatomical context of ONO 1206


Associations of ONO 1206 with other chemical compounds


Gene context of ONO 1206

  • OP-1206 cyclodextrin clathrate (OP-1206 CD: prostaglandin E1 derivate) and ONO-4819 CD (a highly selective EP4 agonist) were intravenously administrated [20].
  • These findings suggest an important role for ADF in the OP-1206-dependent suppression of retinal tissue damage caused by oxidative insult [3].
  • We also observed a short-term effect of limaprost on renal hemodynamics in three cases with diabetic nephropathy [12].

Analytical, diagnostic and therapeutic context of ONO 1206


  1. Rapid effect of oral limaprost in Raynaud's disease in childhood. Shono, T., Ikeda, K. Lancet (1989) [Pubmed]
  2. Protective effect of a synthetic analog of prostaglandin E(1) on the small intestinal damage induced by the administration of methotrexate to rats. Gao, F., Nakamaru, M., Masubuchi, Y., Horie, T. Journal of pharmaceutical sciences. (2001) [Pubmed]
  3. Analysis of localization of adult T-cell leukemia-derived factor in the transient ischemic rat retina after treatment with OP-1206 alpha-CD, a prostaglandin E1 analogue. Yamamoto, M., Ohira, A., Honda, O., Sato, N., Furuke, K., Yodoi, J., Honda, Y. J. Histochem. Cytochem. (1997) [Pubmed]
  4. OP-1206, a prostaglandin E1 derivative, attenuates the thermal hyperesthesia induced by constriction injury to the sciatic nerve in the rat. Yamamoto, T., Shimoyama, N., Asano, H., Mizuguchi, T. Anesth. Analg. (1995) [Pubmed]
  5. The effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model. Nakai, K., Takenobu, Y., Eguchi, K., Takimizu, H., Honjo, K., Akimaru, S., Maegawa, H., Marsala, M., Katsube, N. Anesth. Analg. (2002) [Pubmed]
  6. Effect of oral administration of prostaglandin E1 on erectile dysfunction. Sato, Y., Horita, H., Adachi, H., Suzuki, N., Tanda, H., Kumamoto, Y., Tsukamoto, T. British journal of urology. (1997) [Pubmed]
  7. Amelioration of nerve Na(+)-K(+)-ATPase activity independently of myo-inositol level by PGE1 analogue OP-1206.alpha-CD in streptozocin-induced diabetic rats. Sonobe, M., Yasuda, H., Hisanaga, T., Maeda, K., Yamashita, M., Kawabata, T., Kikkawa, R., Taniguchi, Y., Shigeta, Y. Diabetes (1991) [Pubmed]
  8. Inhibition of platelet aggregation by the cAMP-phosphodiesterase inhibitor, cilostamide, may not be associated with activation of cAMP-dependent protein kinase. Nishikawa, M., Komada, F., Morita, K., Deguchi, K., Shirakawa, S. Cell. Signal. (1992) [Pubmed]
  9. Stimulation of intestinal epithelial restitution by prostaglandin E(1) analogue. Hirata, K., Horie, T. Cancer Chemother. Pharmacol. (2003) [Pubmed]
  10. Effect of a prostaglandin E1 derivative (OP-1206) and acetylsalicylic acid on electrically induced thrombosis in guinea-pig mesenteric artery and its modification by an inhibitor of prostaglandin I2 synthetase, tranylcypromine. Fujitani, B., Watanabe, M., Kuwashima, J., Tsuboi, T., Kadokawa, T., Kitagawa, T. Jpn. J. Pharmacol. (1986) [Pubmed]
  11. Pharmacological evaluation of OP 1206, a prostaglandin E1 derivative, as an antianginal agent. Tsuboi, T., Hatano, N., Nakatsuji, K., Fujitani, B., Yoshida, K., Shimizu, M., Kawasaki, A., Sakata, M., Tsuboshima, M. Archives internationales de pharmacodynamie et de thérapie. (1980) [Pubmed]
  12. Possible participation of a prostaglandin E1 analogue in the aggravation of diabetic nephropathy. Aoki, Y., Yanagisawa, Y., Oguchi, H., Yazaki, K., Furuta, S. Diabetes Res. Clin. Pract. (1992) [Pubmed]
  13. Effects of OP-1206 (prostaglandin E1) on nerve-conduction velocity in the dog cauda equina subjected to acute experimental compression. Konno, S., Kayama, S., Olmarker, K., Kikuchi, S. Journal of spinal disorders. (1996) [Pubmed]
  14. Reversal of vasopressin-induced coronary vasoconstriction by a PGE1 analogue (ONO 1206) in primates. Kottegoda, S.R., Adaikan, P.G., Karim, S.M. Prostaglandins, leukotrienes, and medicine. (1982) [Pubmed]
  15. Correlation between methotrexate-induced intestinal damage and decrease in polyamine content. Gao, F., Tomitori, H., Igarashi, K., Horie, T. Life Sci. (2002) [Pubmed]
  16. A synthetic analog of prostaglandin E(1) prevents the production of reactive oxygen species in the intestinal mucosa of methotrexate-treated rats. Gao, F., Horie, T. Life Sci. (2002) [Pubmed]
  17. Effect of a synthetic analog of prostaglandin E1 on the intestinal mucosa of methotrexate-treated rats. Gao, F., Ueda, S., Horie, T. Anticancer Res. (2001) [Pubmed]
  18. A prostaglandin E1 analog, OP-1206, alleviates 5-fluorouracil-induced injury of rat small intestine. Hirata, K., Horie, T. Res. Commun. Mol. Pathol. Pharmacol. (1999) [Pubmed]
  19. Some pharmacological effects of 17(S) methyl-omega-homo-trans-delta2-PGE1 (ONO 1206). Adaikan, P.G., Karim, S.M. Prostaglandins and medicine. (1981) [Pubmed]
  20. Effects on improvement of blood flow in the chronically compressed cauda equina: comparison between a selective prostaglandin E receptor (EP4) agonist and a prostaglandin E1 derivate. Sekiguchi, M., Konno, S., Kikuchi, S. Spine. (2006) [Pubmed]
  21. Effectiveness of prostaglandin e1 for the treatment of patients with neuropathic pain following herpes zoster. Kanai, A., Osawa, S., Suzuki, A., Ishimaru, R., Hoka, S. Pain medicine (Malden, Mass.) (2007) [Pubmed]
WikiGenes - Universities